Drug
Ubt251
Ubt251: highest development phase Phase 1, developed by Novo Nordisk. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Novo Nordisk
Trials
| Drug | Phase | Indication |
|---|---|---|
| UBT251 NCT07710768 | Phase 1 | Obesity |
Latest
No recent events.
Follow Ubt251 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.